These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Kuzuya T; Nakagawa S; Satoh J; Kanazawa Y; Iwamoto Y; Kobayashi M; Nanjo K; Sasaki A; Seino Y; Ito C; Shima K; Nonaka K; Kadowaki T; Diabetes Res Clin Pract; 2002 Jan; 55(1):65-85. PubMed ID: 11755481 [TBL] [Abstract][Full Text] [Related]
25. Imeglimin: A New Promising and Effective Weapon in the Treatment of Type 2 Diabetes. Doupis J; Baris N; Avramidis K touchREV Endocrinol; 2021 Nov; 17(2):88-91. PubMed ID: 35118453 [TBL] [Abstract][Full Text] [Related]
26. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors. Rahelić D; Javor E; Lucijanić T; Skelin M Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028 [TBL] [Abstract][Full Text] [Related]
27. Gycemic control, mealtime glucose excursions, and diabetic complications in type 2 diabetes mellitus. Palumbo PJ Mayo Clin Proc; 2001 Jun; 76(6):609-18. PubMed ID: 11393500 [TBL] [Abstract][Full Text] [Related]
28. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Krentz AJ; Bailey CJ Drugs; 2005; 65(3):385-411. PubMed ID: 15669880 [TBL] [Abstract][Full Text] [Related]
29. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy. Vinik A Clin Ther; 2007; 29 Spec No():1236-53. PubMed ID: 18046925 [TBL] [Abstract][Full Text] [Related]
30. In Vitro Investigation, Pharmacokinetics, and Disposition of Imeglimin, a Novel Oral Antidiabetic Drug, in Preclinical Species and Humans. Clémence C; Fouqueray P; Sébastien B Drug Metab Dispos; 2020 Dec; 48(12):1330-1346. PubMed ID: 33020063 [TBL] [Abstract][Full Text] [Related]
32. Glucose-Lowering Effects of Imeglimin and Its Possible Beneficial Effects on Diabetic Complications. Yanai H; Adachi H; Hakoshima M; Katsuyama H Biology (Basel); 2023 May; 12(5):. PubMed ID: 37237539 [TBL] [Abstract][Full Text] [Related]
33. Novel approaches to pharmacological management of type 2 diabetes in Japan. Kaneko S Expert Opin Pharmacother; 2021 Nov; 22(16):2235-2249. PubMed ID: 34461791 [TBL] [Abstract][Full Text] [Related]
34. Development of Imeglimin Electrospun Nanofibers as a Potential Buccal Antidiabetic Therapeutic Approach. Alamer AA; Alsaleh NB; Aodah AH; Alshehri AA; Almughem FA; Alqahtani SH; Alfassam HA; Tawfik EA Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111693 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment. Chevalier C; Dubourg J; Bolze S; Fouqueray P Clin Pharmacokinet; 2021 Apr; 60(4):485-490. PubMed ID: 33169345 [TBL] [Abstract][Full Text] [Related]
36. Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes. Tomita Y; Hansson E; Mazuir F; Wellhagen GJ; Ooi QX; Mezzalana E; Kitamura A; Nemoto D; Bolze S Clin Transl Sci; 2022 Apr; 15(4):1014-1026. PubMed ID: 34962074 [TBL] [Abstract][Full Text] [Related]
37. Managing type 2 diabetes: going beyond glycemic control. Stolar MW; Hoogwerf BJ; Gorshow SM; Boyle PJ; Wales DO J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582 [TBL] [Abstract][Full Text] [Related]
38. Mitochondrial Dysfunction and Imeglimin: A New Ray of Hope for the Treatment of Type-2 Diabetes Mellitus. Swain J; Jadhao P; Sravya SL; Teli B; Lavanya K; Singh J; Sahoo A; Das S Mini Rev Med Chem; 2023 Oct; ():. PubMed ID: 37861052 [TBL] [Abstract][Full Text] [Related]
39. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Koro CE; Bowlin SJ; Bourgeois N; Fedder DO Diabetes Care; 2004 Jan; 27(1):17-20. PubMed ID: 14693960 [TBL] [Abstract][Full Text] [Related]
40. Recent and emerging therapeutic medications in type 2 diabetes mellitus: incretin-based, Pramlintide, Colesevelam, SGLT2 Inhibitors, Tagatose, Succinobucol. Lo MC; Lansang MC Am J Ther; 2013; 20(6):638-53. PubMed ID: 20838206 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]